Achim Hoerauf

Achim Hoerauf

Auto-generated profile, based on publicly available information

Achim Hoerauf

Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, Bonn, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2007 in Medical Microbiology and Immunology
Verified
Journal Article
Open access
PDF file
AHAchim Hoerauf
Achim Hoerauf
SSSabine Specht
Sabine Specht
MBMarcelle Büttner
Marcelle Büttner
KPKenneth Pfarr
Kenneth Pfarr
SMSabine Mand
Sabine Mand
DBDietrich W. Büttner
Dietrich W. Büttner
In a randomized, placebo-controlled trial in Ghana, 67 onchocerciasis patients received 200-mg/day doxycycline for 4–6 weeks, followed by ivermectin (IVM) after 6 months. After 6–27 months, efficacy was evaluated by onchocercoma histology, PCR and microfilariae determination. Administration of doxycycline resulted in endobacteria depletion and female worm sterilization. The 6-week treatment was macrofilaricidal, with >60% of the female worms found dead, despite the presence of new, Wolbachia-containing worms acquired after the administration of doxycycline. Doxycycline may be developed as second-line drug for onchocerciasis, to be administered in areas without transmission, in foci with IVM resistance and in areas with Loa co-infections.

1 December 2008 in Current Opinion in Infectious Diseases
Verified
Journal Article
Closed access
AHAchim Hoerauf
Achim Hoerauf
Chemotherapy against onchocerciasis and lymphatic filariasis has been discussed mainly within the framework of mass drug administration with diethylcarbamazine, ivermectin and albendazole. Although strong reductions in infection prevalence were achieved, the regimes for these drugs do not fully cover needs of individual patients who seek treatment because of symptoms. Chemotherapy against filarial Wolbachia endosymbionts with doxycycline showed higher antiparasitic efficacy in onchocerciasis and lymphatic filariasis and also improved disease. This review details the recent indications for this new treatment, focussing on regimes for individual drug administration. A regimen of 6-week/100 mg doxycycline per day sterilized adult female Onchocerca volvulus. Two hundred milligrams doxycycline per day for 4 or 6 weeks revealed 50 and 60% macrofilaricidal effects, respectively. Reduction of 80-90% of adult worms was observed in bancroftian filariasis with 200 mg/day doxycycline for 4 or 6 weeks. The latter regimen showed reduction of lymph vessel dilation and of hydrocele. Lymphoedema progression was halted and reversed in early stages. Different options for antiwolbachial individual drug administration are summarized here. With improving health systems in endemic countries, individuals will demand best-possible treatment and accelerate a shift from mass drug administration-only approaches to integrated approaches combining both mass drug administration and individual drug administration. Treatment may be further improved by new antibiotics detected in high-throughput settings.

20 September 2005 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
AHA. Hoerauf
A. Hoerauf
JSJ. Satoguina
J. Satoguina
MSM. Saeftel
M. Saeftel
SSS. Specht
S. Specht

15 September 2006 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
Alexander Yaw DebrahAlexander Yaw Debrah
Alexander Yaw Debrah
SMSabine Mand
Sabine Mand
SSSabine Specht
Sabine Specht
YMYeboah Marfo-Debrekyei
Yeboah Marfo-Debrekyei
LDLinda B. Debrah
Linda B. Debrah
AHAchim Hoerauf
Achim Hoerauf
Lymphatic filariasis is a disease of considerable socioeconomic burden in the tropics. Presently used antifilarial drugs are able to strongly reduce transmission and will thus ultimately lower the burden of morbidity associated with the infection, however, a chemotherapeutic principle that directly induces a halt or improvement in the progression of the morbidity in already infected individuals would constitute a major lead. In search of such a more-effective drug to complement the existing ones, in an area endemic for bancroftian filariasis in Ghana, 33 microfilaremic and 18 lymphedema patients took part in a double-blind, placebo-controlled trial of a 6-wk regimen of 200 mg/day doxycycline. Four months after doxycycline treatment, all patients received 150–200 μg/kg ivermectin and 400 mg albendazole. Patients were monitored for Wolbachia and microfilaria loads, antigenemia, filarial dance sign (FDS), dilation of supratesticular lymphatic vessels, and plasma levels of lymphangiogenic factors (vascular endothelial growth factor-C [VEGF-C] and soluble vascular endothelial growth factor receptor-3 [(s)VEGFR-3]). Lymphedema patients were additionally monitored for stage (grade) of lymphedema and the circumferences of affected legs. Wolbachia load, microfilaremia, antigenemia, and frequency of FDS were significantly reduced in microfilaremic patients up to 24 mo in the doxycycline group compared to the placebo group. The mean dilation of supratesticular lymphatic vessels in doxycycline-treated patients was reduced significantly at 24 mo, whereas there was no improvement in the placebo group. Preceding clinical improvement, at 12 mo, the mean plasma levels of VEGF-C and sVEGFR-3 decreased significantly in the doxycycline-treated patients to a level close to that of endemic normal values, whereas there was no significant reduction in the placebo patients. The extent of disease in lymphedema patients significantly improved following doxycycline, with the mean stage of lymphedema in the doxycycline-treated patients being significantly lower compared to placebo patients 12 mo after treatment. The reduction in the stages manifested as better skin texture, a reduction of deep folds, and fewer deep skin folds. In conclusion, a 6-wk regimen of antifilarial treatment with doxycycline against W. bancrofti showed a strong macrofilaricidal activity and reduction in plasma levels of VEGF-C/sVEGFR-3, the latter being associated with amelioration of supratesticular dilated lymphatic vessels and with an improvement of pathology in lymphatic filariasis patients. Lymphatic filariasis, caused by filarial worms, is transmitted by mosquitoes. The infection leads to pathology such as edema of the legs (lymphedema) or the scrotum (hydrocele). About 120 million people are estimated to be infected, and 1.2 billion are at risk of infection. The currently used drugs (diethylcarbamazine [DEC] or ivermectin plus albendazole) to treat the disease are able to kill most of the larval stage (microfilariae) in the blood but have either no (ivermectin) or partial (DEC) effect on the adult worms that cause the pathology. They also do not sufficiently halt the progression of pathology, such as, lymph vessel dilation, hydrocele, and lymphedema. In search of a more effective drug capable of killing the adult worms, and also of halting the progression of the disease in already infected individuals, the authors recruited, in an endemic area in Ghana, 33 people who were infected with the worm and microfilaremic but had not yet developed the disease, as well as 18 lymphedema patients, and treated them with either 200 mg/d doxycycline or matching placebo for 6 wk. The findings presented here reveal that doxycycline is able to kill the adult worms, improves lymphatic vessel dilation, and ameliorates the conditions of lymphedema patients significantly. This suggests that doxycycline can be used to treat lymphatic filarial infections and pathology, making doxycycline the first drug already approved for human use and considered for use as an adjunct to current control programs, which in addition to parasite control achieves improvement of the quality of life of persons with pathology.

15 April 2006 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JTJoseph Turner
Joseph Turner
SMSabine Mand
Sabine Mand
Alexander Yaw DebrahAlexander Yaw Debrah
Alexander Yaw Debrah
JMJohannes Muehlfeld
Johannes Muehlfeld
KPKenneth Pfarr
Kenneth Pfarr
AHAchim Hoerauf
Achim Hoerauf
Background. Eight- and 6-week courses of doxycycline are superior to standard treatment of bancroftian filariasis. Standard treatment (albendazole pl

7 November 2008 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
JSJudith S. Satoguina
Judith S. Satoguina
Tomabu AdjobimeyTomabu Adjobimey
Tomabu Adjobimey
KAKathrin Arndts
Kathrin Arndts
JHJochen Hoch
Jochen Hoch
JOJohannes Oldenburg
Johannes Oldenburg
AHAchim Hoerauf
Achim Hoerauf
Regulatory T cells exert their function through the modulation of both T and B cell responses. Our previous studies demonstrated that IL‐10‐producing Treg (Tr1) can induce B cells to secrete IgG4 in a cell‐contact‐dependent manner. The benefit of such non‐inflammatory B‐cell responses is apparent in the hyporesponsive state of patients with helminth infections such as Onchocerciasis. Here, we investigated the mechanisms involved to induce IgG4, within B:Tr‐cell co‐cultures, using IL‐10‐producing tetanus‐toxoid‐specific regulatory T cell lines and clones (Tr‐TCC) from human PBMC. During the generation process, we found that increasing Foxp3 levels in regulatory T cell lines correlated with their ability to induce IgG4 in B cells. Using Tr‐TCC, we found that blocking glucocorticoid‐induced tumour necrosis factor receptor‐related protein (GITR) molecules selectively prevented IgG4 production as did neutralizing Ab to glucocorticoid‐induced tumour necrosis factor receptor‐related protein ligand (GITR‐L), IL‐10 and TGF‐β. Furthermore, the prevention of IgG4 induction by anti‐GITR Ab was reversed by excess rIL‐10 but not rTGF‐β. In contrast, anti‐ICOS and anti‐CTLA‐4 Abs had no effect. When compared with Tr‐TCC, freshly isolated CD4+CD25+ T cells, but not effector T cell populations, induced low levels of IgG4, which were also blocked by anti‐GITR and anti‐GITR‐L Ab. Thus, the mechanism of IgG4 induction by regulatory cells involves GITR–GITR‐L interactions, IL‐10 and TGF‐β.